ArticleOncotarget2020

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.

Konrad Klinghammer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.